Structure, functions of p-glycoprotein and its role in rational pharmacotherapy
- Authors: Yakusheva E.N.1, Shulkin A.V.1, Popova N.M.1, Chernyh I.V.1, Titov D.S.1
-
Affiliations:
- Ryazan State Medical University
- Issue: Vol 12, No 2 (2014)
- Pages: 3-11
- Section: Articles
- Submitted: 21.10.2015
- Published: 15.06.2014
- URL: https://journals.eco-vector.com/RCF/article/view/736
- DOI: https://doi.org/10.17816/RCF1223-11
- ID: 736
Cite item
Full Text
Abstract
Keywords
About the authors
Elena Nikolaevna Yakusheva
Ryazan State Medical University
Email: e.yakusheva@rzgmu.ru
M. D., associate professor, head of the chair of pharmacology with a course of pharmacy and pharmacotherapy of faculty of additional professional education
Aleksey Vladimirovich Shulkin
Ryazan State Medical University
Email: alekseyshulkin@rambler.ru
Ph. D., assistant of the chair of pharmacology with a course of pharmacy and pharmacotherapy of faculty of additional professional education
Natal’ya Mikhaylovna Popova
Ryazan State Medical University
Email: p34-66@yandex.ru
Ph. D., assistant of the chair of pharmacology with a course of pharmacy and pharmacotherapy of faculty of additional professional education
Ivan Vladimirovich Chernyh
Ryazan State Medical University
Email: ivchernykh88@mail.ru
assistant of the chair of the general chemistry with a course of bioorganic and organic chemistry
Dmitriy Sergeevich Titov
Ryazan State Medical University
Email: i3762@yandex.ru
graduate student of the chair of pharmacology with a course of pharmacy and pharmacotherapy of faculty of additional professional education
References
- Бирюкова А. С., Якушева Е. Н., Щулькин А. В., Никифорова Л. В. Влияние тироксина на функциональную активность гликопротеина-Р в эксперименте // Российский медико-биологический вестник имени академика И. П. Павлова. - 2011. - № 4. - P. 49-53.
- Кукес В. Г., Грачев С. В., Сычев Д. А., Раменская Г. В. Метаболизм лекарственных средств. Научные основы персонализованной медицины: руководство для врачей. - М.: ГЭОТАР-Медиа, 2008.
- Середенин С. Б. Лекции по фармакогенетике. - М.: МИА, 2004.
- Штиль А. А. Развитие множественно лекарственной устойчивости как срочный ответ клетки на экзогенные воздействия // Биологические мембраны. - 2003. - Т. 20, № 3. - С. 236-243.
- Якушева Е. Н., Черных И. В., Бирюкова А. С. Характеристика гликопротеина-P как белка-транспортера лекарственных веществ // Российский медико-биологический вестник имени академика И. П. Павлова. - 2011. - № 3. - P. 142-148.
- Якушева Е. Н., Черных И. В. Влияние финастерида на функциональную активность гликопротеина-P в эксперименте // Российский медико-биологический вестник имени академика И. П. Павлова. - 2012. - № 4. - P. 46-50.
- Aller S. G., Yu J., Ward A. et al. Structure of P-glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding // Science. - 2009. - Vol. 323, № 5922. - P. 1718-1722.
- Al-Shawi M. K., Polar M. K., Omote N. et al. Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein // Biol. Chem. - 2003. - Vol. 278. - P. 52629-52640.
- Ambudkar S. V., Kim I. V., Sauna Z. E. The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1) // Eur. J. Farm. Sci. - 2006. - Vol. 27, № 5. - P. 392-400.
- Ambudkar S. V., Dey S., Hrycyna C. et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter // Annu. Rev. Pharmacol. Toxicol. - 1999. - Vol. 39. - P. 361-398.
- Balram C., Huihua Li, Machin D. et al. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression // Br. J. Clin. Pharm. - 2005. - Vol. 60, № 2. - P. 159-171.
- Callaghan R., Berridge G., Ferry D. R., Higgins C. F. The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface // Biochim. Biophys. Acta. - 1997. - Vol. 1328. - P. 109.
- Callen D. F., Baker E., Simmers R. N. et al. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1 // Hum. Genet. - 1987. - Vol. 77. - P. 142-144.
- Carrigos M., Mir L. M., Orlowski S. Competitive and Non-Competitive Inhibition of the Multidrug-Resistance-Associated P-glycoprotein ATPase // Eur. J. Biochem. - 1997. - Vol. 244, № 2. - P. 664-673.
- Chin L. W., Kroetz D. L. P-gp pharmacogenetics: progress, pitfalls and promise // Clin. Pharmacol. Ther. - 2007. - Vol. 81, № 2. - P. 265-269.
- Choi Y. H., Yu A. M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development // Curr. Pharm. Des. - 2013 May 13. URL: http://www.ncbi.nlm.nih.gov/pubmed/23688078 (дата обращения 22.12.2013).
- Chung J. W., Yang S. H., Choi J. S. Effects of lovastatin on the pharmacokinetics of nicardipine in rat // Biopharm. Drug Dispos. - 2010. - Vol. 31, № 7. - P. 436-341.
- Comerford K. M., Wallace T. J., Karhausen J. et al. Hypoxia-inducible Factor-1-dependent Regulation of the Multidrug Resistance (MDR1) Gene // Cancer Res. - 2002. - Vol. 62. - P. 3387.
- Ecker G. F., Stockner T., Chiba P. Computational models for prediction of interactions with ABC-transporters // Drug Discov Today - 2008. - Vol. 13, № 7-8. - P. 311-317.
- Ekins S., Kim R. B., Leake B. F. et al. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates // Mol Pharmacol. - 2002. - Vol. 61, № 5. - P. 974-981.
- Frankfurt O. S., Seckinger D., Sugarbaker E. V. Intercellular transfer of drug resistance // Cancer Res. - 1991. - Vol. 51, № 4. - P. 1190-1195.
- Geick A., Eichelbaum M., Burk O. Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin // J. Biol. Chem. - 2001. - Vol. 276. - P. 14581-14587.
- Germann U. A., Chambers T. C., Ambudcar S. V. et al. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells // Biol. Chem. - 1996. - Vol. 271. - P. 1708-1716.
- Glavy J. S., Horwitz S. B., Orr G. A. Identification of the in vivo phosphorylation sites for acidic-directed kinases in murine mdr1b P-glycoprotein // Biol. Chem. - 1997. - Vol. 272. - P. 5909-5914.
- Hamilton K. O., Yazdanian M. A., Audus K. L. Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands // Int. J. Pharm. - 2001. - Vol. 228, № 1-2. - P. 171-179.
- Hoffmeyer S., Burk O., von Richter O. et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo // Proc. Nat. Acad. Sci. - 2000. - Vol. 97, № 7. - P. 3473-3478.
- Hrycyna C. A., Ramachandra M., Ambudkar S. V. et al. Mechanism of action of human P-glycoprotein ATPase activity photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites // J. Biol. Chem. - 1998. - Vol. 273. - P. 16631-16634.
- Hudachek S. F., Gustafson D. L. Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice // J. Pharmacokinet. Pharmacodyn. - 2013. - Vol. 40, № 4. - P. 437-449.
- Jaganathan S. K. Can flavonoids from honey alter multidrug resistance? // Med. Hypotheses. - 2011. - Vol. 76, № 4. - P. 535-537.
- Jin S. Transcriptional Regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y // Mol. Cell. Biol. - 1998. - Vol. 18. - P. 4377-4384.
- Juliano R. L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell nutans // Biochem. Biophis. Acta - 1976. - Vol. 455, № 1. - P. 155-162.
- Kitada K., Yamasaki T. The MDR1/ABCB1 regional amplification in large inverted repeats with asymmetric sequences and microhomologies at the junction sites // Cancer Genet. Cytogenet. 2007. - Vol. 178, № 2. - P. 120-127.
- Kitada K., Yamasaki T., Aikawa S. Amplification of the ABCB1 region accompanied by a short sequence of 200bp from chromosome 2 in lung cancer cells // Cancer Genet. Cytogenet. - 2009. - Vol. 194, № 1. - P. 4-11.
- Klepsch F., Chiba P., Ecker G. F. Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein // PLoS Comput. Biol. - 2011. - Vol. 7, № 5. - e1002036.
- Klopman G., Shi L. M., Ramu A. Quantitative structure-activity relationship of multidrug resistance reversal agents // Mol. Pharmacol. - 1997. - Vol. 52. - P. 323.
- Kramer R., Weber T. K., Arceci R. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype // Br. J. Cancer. - 1993. - Vol. 71. - P. 670-676.
- Lee C. Y., Lai T. Y., Wu Y. M. et al. Gene expression of P-glycoprotein and cytochrome P450 3a4 in peripheral blood mononuclear cells and correlation with expression in liver // Transplant. Proc. - 2010. - Vol. 42, № 3. - P. 834-836.
- Lerner-Marmarosh N., Gimi K., Urbatsch I. L. et al. Large scale purification of detergent-soluble P-glycoprotein from Pichia pastoris cells and characterization of nucleotide binding properties of wild-type, Walker A, and Walker B mutant proteins // Biol. Chem. - 1999. - Vol. 274. - P. 34711-34718.
- Levchenko A., Mehta B. M., Niu X. et al. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells // Proc. Natl. Acad. Sci. USA. - 2005. - Vol. 102, № 6. - P. 1933-1938.
- Loo T. W., Bartlett M. C., Clark D. M. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding // Biol. Chem. - 2003. - Vol. 278, № 16. - P. 13603-13606.
- Loo T. W., Clarke D. M. Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein // J. Biol. Chem. -1994. - Vol. 269. - P. 7243-7248.
- Miller B. E., Machemer T., Lehotan M. et al. Tumor subpopulation interactions affecting melphalan sensitivity in palpable mouse mammary tumors // Cancer Res. - 1991. - Vol. 51, № 16. - P. 4378-4387.
- Miyazaki M., Kohno K., Uchiumi T. et al. Activation of human multidrug resistance-1 gene promoter in response to heat shock stress // Biochem. Biophys. Res. Commun. - 1992. - Vol. 187. - P. 677-684.
- Pajeva I. K., Globisch C., Wiese M. Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors // Chem. Med. Chem. - 2009. - Vol. 4, № 11. - P. 1883-1896.
- Poongavanam V., Haider N., Ecker G. F. Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors // Bioorg. Med. Chem. - 2012. - Vol. 20, № 18. - P. 5388-5395.
- Robinson L. J., Roberts W. K., Ling T. T. et al. Human MDR1 protein over expression delays the apoptotic cascade in Chinese hamster ovary fibroblasts // Biochem. - 1997. - Vol. 36. - P. 11169-11178.
- Safa A. R., Stern R. K., Choy K. et al. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185-- Val-185 substitution in P-glycoprotein // Proc. Natl. Acad. Sci USA. - 1990. - Vol.87, № 18. - P.7225-7229.
- Schinkel A. H. et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug, transporting) P-glycoproteins // Proc. natl. acad. sci. - 1997. - Vol. 94. - P. 4028-4033.
- Schinkel A. H., Kemp S., Dolle M. et al. N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein // Biol. Chem. - 1993. - Vol. 268, № 10. - Р. 7474-7481.
- Schwab M., Eichelbaum M., Fromm M. F. Genetic polymorphisms of the humanmdr1 drug transporter // Annu. Rev. Pharmacol. Toxicol. - 2003. - Vol. 43. - P. 285-307.
- Scotto K. W., Egan D. Transcriptional regulation of MDR genes // Cytotechnology. - 1998. - Vol. 27. - P. 257-269.
- Shapiro A. B., Ling V. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein // Eur. J. Biochem. - 1998. - Vol. 254. - P. 189-193.
- Sharom F. J. The P-glycoprotein multidrug transporter // Essays. Biochem. - 2011. - Vol. 50. - P. 161-178.
- Stein U., Walther W., Shoemaker R. N. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance // Br. J. Cancer. - 1996. - Vol.74, № 9. - P. 1384-1391.
- Tofilon P. J., Buckley N., Deen D. F. Effect of cell-cell interactions on drug sensitivity and growth of drug-sensitive and -resistant tumor cells in spheroids // Science. - 1984. - Vol. 226, № 4676. - P. 862-864.
- U. S. Food and Drug Administration, Center for Drug Evaluationand Research. Guidance for industry: drug interaction studiesdstudy design, data analysis, implications for dosing, and labeling recommendations. URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362. Pdf (дата обращения 22.12.2013)
- Ueda K., Okamura N., Hirai M. et al. Human P-glycoprotein transports cortisol, aldosterone, anddexamethasone, but not progesterone // J. Biochem. - 1992. - Vol. 267, № 34. - P. 24248-24252.
- Ueda K., Taguchi Y., Morishima M. How does P-glycoprotein recognize its substrates // Semin. Cancer. Biol. - 1997. - Vol. 8. - P. 151-159.
- Ushigome F., Takanaga H., Matsuo H. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein // Eur. J. Pharmacol. - 2000. - Vol. 408, № 1. - P. 1-10.
- Van der Kolk D. M., de Vries E. G. E., van Putten W. L. J. et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia // Clin. Cancer Res. - 2000. - Vol. 6. - P. 3205-3214.
- Vilaboa N. E., Galan A., Troyano A. et al. Regulation ofmultidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). // J. Biol. Chem. - 2000. - Vol. 275. - P. 24970-24976.
- Wang Z., Chen Y., Liang H. et al. P-glycoprotein substrate models using support vector machines based on a comprehensive data set // J. Chem. Inf. Model. - 2011. - Vol. 51, № 6. - P. 1447-1456.
- Wartenberg M., Gronczynska S., Bekhite M. M. et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species // FASEB J. - 2003. - Vol. 17, № 3. - P. 503-505.
- Wessler D. J., Grip L. T., Mendell J., Giugliano R. P. The P-Glycoprotein Transport System and Cardiovascular Drugs // JACC. - 2013. - Vol. 61, № 25. - P. 2495-502.
- Yague E., Armesilla A. L. Harrison J. et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation // Biol. Chem. - 2003. - Vol. 278. - P. 10344-10352.
- Yang C. P., Cohen D., Greenberger L. M. et al. Differential transport properties of two mdr gene products are distinguished by progesterone // J. Biol. Chem. - 1990. - Vol.265, № 18. - P. 10282-10288.
- Yang C. P., DePinho S. G., Greenberger L. M. et al. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus // J. Biol. Chem. - 1989. - Vol. 264, № 2. - P. 782-728.
- Yuan H., Yang K., Li Y. et al. The structure and function of P-glycoprotein // Curr. Med. Chem. - 2010. - Vol. 17, № 8. - Р. 786-800.
- Z. Zhang, Wu J. Y., Hait W. N. et al. Regulation of the stability of P-glycoprotein by ubiquitination // Mol. Pharmacol. - 2004. - Vol. 66. - P. 395-403.
- Zhou S. F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition // Xenobiot. - 2008. - Vol. 8, № 7-8. - P. 802-832.